Peppard J V, Knap A K
Arthritis Biology Research, Novartis Institute for Biomedical Research, Summit, New Jersey 07901, USA.
In Vitro Cell Dev Biol Anim. 1999 Sep;35(8):459-64. doi: 10.1007/s11626-999-0052-2.
The effects were measured and compared of three nonselective cysteine cathepsin inhibitors (leupeptin, trans-Epoxy-succinyl-L-Leucylamido(4-guanidino)-butane (E-64), and Z-Phe-Ala-CH2F) and a selective cathepsin B inhibitor, CA074Me, on the intracellular processing of 125I-labeled human recombinant Interleukin 6 (IL-6) by HepG2 cells. The uptake and processing of 125I-IL-6 by cells treated with inhibitors was followed over a 7-h period. All inhibitors caused an increased residence time of IL-6 inside the cell and a corresponding decrease in the output of non-trichloroacetic acid-precipitable fragments of radiolabeled protein. Maximal effect was achieved with leupeptin at 200 microM, with which the rate of IL-6 digestion was reduced to 50% that of control cells. The specific inhibitor CA074Me was the least effective in slowing the intracellular processing of IL-6. The effects of all of the inhibitors on the production of haptoglobin, either stimulated by IL-6 or basal, was negligible over a similar time period, indicating continued cell viability. The data from this model suggest that cathepsin inhibitors would not interfere with lysosomal processing to an extent which would prohibit the development of selective and potent cathepsin inhibitors for the treatment of diseases in which individual cysteine cathepsins play clearly pathophysiological roles.
研究了三种非选择性半胱氨酸组织蛋白酶抑制剂(亮抑酶肽、反式环氧琥珀酰-L-亮氨酰胺基(4-胍基)丁烷(E-64)和Z-苯丙氨酸-丙氨酸-CH2F)以及一种选择性组织蛋白酶B抑制剂CA074Me对HepG2细胞处理125I标记的人重组白细胞介素6(IL-6)细胞内过程的影响。在7小时内跟踪了用抑制剂处理的细胞对125I-IL-6的摄取和处理情况。所有抑制剂均导致IL-6在细胞内的停留时间增加,放射性标记蛋白的非三氯乙酸沉淀片段输出相应减少。亮抑酶肽在200μM时达到最大效果,此时IL-6的消化速率降至对照细胞的50%。特异性抑制剂CA074Me在减缓IL-6细胞内处理方面效果最差。在相似时间段内,所有抑制剂对由IL-6刺激或基础状态下触珠蛋白产生的影响可忽略不计,表明细胞仍具有活力。该模型的数据表明,组织蛋白酶抑制剂对溶酶体处理的干扰程度不会达到禁止开发用于治疗个别半胱氨酸组织蛋白酶发挥明确病理生理作用疾病的选择性强效组织蛋白酶抑制剂的程度。